聚ADP核糖聚合酶
前列腺癌
PARP抑制剂
医学
雄激素受体
DNA修复
癌症研究
DNA损伤
癌症
聚合酶
生物信息学
基因
内科学
DNA
遗传学
生物
作者
Ossian Longoria-Lozano,Nick Beije,Johann S. de Bono
标识
DOI:10.1053/j.seminoncol.2023.09.003
摘要
Poly(ADP-ribose) polymerase (PARP) inhibitors have transformed the treatment landscape for patients with metastatic castration-resistant prostate cancer (mCRPC) and alterations in DNA damage response genes. This has also led to widespread use of genomic testing in all patients with mCRPC. The current review will give an overview of (1) the current understanding of the interplay between DNA damage response and PARP enzymes; (2) the clinical landscape of PARP inhibitors, including the combination of PARP inhibitors with other agents such as androgen-receptor signaling agents; (3) biomarkers related to PARP inhibitor response and resistance; and (4) considerations for interpreting genomic testing results and treating patients with PARP inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI